ChromaDex will provide GBB with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient. NIAGEN is the first and only commercially available form of NR, a naturally-occurring vitamin
With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures,
Under the agreement, Zubsolv will be given preferred, Tier 2 brand status on UHG commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid
Under the terms of the license agreement, Access will receive an upfront licensing fee and double digit royalties on net sales of MuGard in the licensed territory. MuGard
The Phase III clinical program supporting Imbruvica’s early approval contained data that was collected and managed with BioClinica’s web-based solution and provided the Pharmacyclics team instant online access
Parexel provides a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The company’s
The patent includes claims to the use of the company’s drug candidate, Trimesta (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and
Research has shown that ?9-THC, the main active ingredient in medical marijuana, decreases ß-amyloid plaques and neurodegeneration in Alzheimer’s disease, and that it is reduced further by the
The company has established regional hubs in Singapore and Japan to better enable the industry’s growing need to conduct clinical trials in Asia and/or manage global trials from
Macular Health president and CEO Jeffery McAnnally will announce the new product at the 2014 Optometry’s Marketplace at SECO International in Atlanta, Georgia, on 14 March 2014. McAnnally
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.